DENDRITIC CELL AND TUMOR CELL CANCER VACCINES MARKET ANALYSIS

Dendritic Cell and Tumor Cell Cancer Vaccines Market, by Antigen (CD8, CD4, HER2, T-Helper Cell, and Others), by Application (Glioblastoma Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer, Renal Cancer, Lung Cancer, and Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI2753
Formats :
Excel and PDF
Industry : Biotechnology

Dendritic Cell And Tumor Cell Cancer Vaccines MarketSize and Trends

Global Dendritic Cell and Tumor Cell Vaccines Market Drivers

Increase in research and development activities related to dendritic cell and tumor cell based vaccines are expected to accelerate the global dendritic cell and tumor cell vaccines market growth. For instance, in March 2015, Rockefeller University and Memorial Sloan Kettering Cancer Center conducted a phase II study of autologous dendritic cell vaccines (DC/PC3). It is being used as an immunotherapy in the prostate cancer. The vaccine was developed by patient’s own cells.

Furthermore, in April 2016, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) S.r.l., began its study on autologous dendritic cells loaded with autologous tumor homogenate in combination with the drug IL-2. It is being used for the treatment of patients with stage IV colorectal cancer. The purpose of study is to evaluate the consistency of the response of immune cells after completion of the treatment. Currently, the study is in its second phase of clinical trials. Hence, such research and development activities of dendritic cell and tumor cell vaccines are expected to impel the global dendritic cell and tumor cell vaccines market growth.

Approvals of vaccines by regulatory bodies are expected to drive the global dendritic cell and tumor cell vaccines market growth. For instance, in June 2018, Northwest BioTherapeutics received U.S. Food & Drug Administration (FDA) approval for its dendritic cell vaccine, DCVax – L. It is being used for the treatment of cancer type, glioblastoma. Its clinical study revealed that many patients survived for over one and half years after the vaccination. Hence, such approved vaccines based on dendritic cell are expected to drive the global dendritic cell and tumor cell vaccine market growth.